Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study

Abstract

1. •

   Baricitinib, an anti-JAK1/JAK2, reduces cytokine release and SARS-Co-V2 entry.

2. •

   In a retrospective multicenter study baricitinib reduces COVID-19 mortality rate.

3. •

   Baricitinib reduces intensive care unit admissions of COVID-19 pneumonia.

4. •

   Baricitinb reduces SARS-CoV-2 viral burden detected by nasopharyngeal swab.

5. •

   Baricitinib used for 2 weeks was not associated with serious adverse events.

Keywords: Baricitinib; COVID-19; JAK1/2; Pneumonia; Retrospective study; SARS-Co-V2.